SCHEMBL2290159

SCHEMBL2290159

COc1ccc(NC(=O)CON=C2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
KMT2A Q03164 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MAPT P10636 4/20 0.56
LMNA P02545 3/20 0.56
GAA P10253 2/20 0.56
TSHR P16473 2/20 0.53
POLB P06746 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
RECQL P46063 1/20 0.49
MEN1 O00255 2/20 0.49
KDM4E B2RXH2 1/20 0.49
THRB P10828 1/20 0.49
USP2 O75604 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293660 0.92 ALDH1A1 (0.53) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2291103 0.91 KMT2A (0.56) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2295174 0.90 LMNA (0.58) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2291384 0.90 MAPT (0.54) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL8103247 0.90 LMNA (0.55) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2292819 0.90 LMNA (0.55) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2290350 0.88 LMNA (0.53) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2289673 0.88 KMT2A (0.51) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2297370 0.87 ALDH1A1 (0.53) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL2296034 0.87 KMT2A (0.51) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
EP-2164326-A1 AMIDE COMPOUNDS AND THE USE THEREOF Euro-Celtique, S.A. (LU) 2010-03-24 EP disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S ALDH1A1 1349/4885KMT2A 2564/4885SMN1; SMN2 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.